AL102-501
13 evidence topics · 2 sources
Objective
Effect of itraconazole on varegacestat pharmacokinetics in healthy participants
Location and study date
Registry status, dates, and site
| Study characteristic | Quoted record |
|---|---|
| Protocol number | “AL102-501” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2024-11-11” |
| Primary completion (actual) | “2024-12-30” |
| Study completion (actual) | “2025-05-07” |
| First posted | “2024-11-07” |
| Last update posted | “2025-05-11” |
| Site | “Celerion”; “Tempe” |
Study design
Open-label, fixed-sequence, two-period drug-drug interaction study
Registry design fields
| Study characteristic | Quoted record |
|---|---|
| Phase | “Phase 1” |
| Intervention model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |
| Keywords | “Drug-Drug Interaction”; “Pharmacokinetics” |
Eligibility criteria
Healthy adults aged 18 to 55 years
Exclusion criteria
Treatment
Single varegacestat dose alone and with itraconazole 200 mg
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Primary endpoints: varegacestat AUC, Cmax, and Tmax with and without itraconazole
Pharmacokinetic sampling for varegacestat and its metabolite
Secondary endpoints: safety, tolerability, and itraconazole trough concentrations
Strong CYP3A4 inhibitors prohibited in the first-in-human study
“The prohibited concomitant medications included herbal supplements, medications causing Torsades de Pointes, strong inhibitors or inducers of CYP3A4 or P-gp, and sensitive substrates of CYP3A4 with a narrow therapeutic window.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
| Study characteristic | Quoted record |
|---|---|
| Enrollment (actual) | “22” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- AL102-501 is known only from its registry record. The record lists the study as “Completed”, with primary completion on 2024-12-30, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so the effect of itraconazole on varegacestat exposure is unknown from public sources.
- The study is an open-label, single-group, fixed-sequence design in 22 healthy participants aged 18 to 55 years, with women limited to those of non-childbearing potential. Each participant received a single dose of varegacestat alone and then with itraconazole, so the results apply to single-dose exposure in healthy adults.
- The registry record does not state the varegacestat dose given.